Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV F vaccine + aluminum phosphate
- Development stage
- Phase 3
- Lead developer
- Novavax
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The RSV F vaccine + aluminum phosphate is a recombinant respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine formulated with an aluminum phosphate adjuvant. The vaccine targets the conserved F glycoprotein on the RSV surface, which mediates viral fusion with host cell membranes, aiming to elicit a strong immune response and provide protection against RSV infection. The aluminum phosphate acts as an adjuvant to enhance immunogenicity, leading to higher anti-F immunoglobulin G (IgG) antibodies and neutralizing antibodies compared to non-adjuvanted formulations. It has been primarily developed as a maternal immunization strategy, administered intramuscularly to women of childbearing age, to confer passive immunity to infants through transplacental antibody transfer. Clinical trials indicate the combination is well tolerated, immunogenic, and reduces RSV infection rates, though it has not met all efficacy endpoints in large phase 3 studies.
- Brand names
- ResVax
- Other names
- respiratory syncytial virus F protein vaccine + aluminum phosphate
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on RSV F vaccine + aluminum phosphate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV F vaccine + aluminum phosphate.